ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
Oric Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$12.72+0.37 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
124M of 104M shares
Institutional holders
181
31 new, 30 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $2.68M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ott David C. | 8,729,345 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Viking Global Investors LP | 8,264,607 | 7.80% | 13G (passive) amendment | Mar 31, 2026 |
| Rocco Sgobbo | 7,162,637 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
| EcoR1 Capital, LLC | 6,728,116 | 6.90% | 13G (passive) | Jul 29, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 6,596,885 | 7.70% | 13G (passive) | Apr 8, 2025 |
| Viking Global Opportunities Parent GP LLC | 6,572,700 | 9.20% | 13G (passive) amendment | Mar 31, 2025 |
| Bong Y. Koh | 5,676,230 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 5,473,145 | 5.60% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 5,387,783 | 5.40% | 13G (passive) | Mar 31, 2026 |
| Simeon George | 4,615,384 | 5.40% | 13D (active) | May 29, 2025 |
| Steven A. Cohen | 4,401,659 | 5.10% | 13G (passive) | May 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ORIC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 7,162,637 | 6.91% | $77.57M | – | 3.68% |
| BlackRock, Inc. | 6,823,973 | 6.58% | $73.90M | +839,421 | 0.00% |
| EcoR1 Capital, LLC | 6,728,116 | 6.49% | $72.87M | – | 3.54% |
| Price T Rowe Associates Inc /Md/ | 6,617,554 | 6.38% | $71.67K | +1,229,771 | 0.01% |
| Viking Global Investors LP | 5,126,762 | 4.95% | $55.52M | −697,771 | 0.16% |
| State Street Corp | 4,894,000 | 4.72% | $53.00M | +1,191,804 | 0.00% |
| Sr One Capital Management, LP | 4,615,384 | 4.45% | $49.98M | +100,455 | 4.81% |
| VR Adviser, LLC | 4,319,765 | 4.17% | $46.78M | – | 1.42% |
| NEA Management Company, LLC | 4,118,621 | 3.97% | $44.60M | – | 2.81% |
| Vanguard Capital Management LLC | 3,951,169 | 3.81% | $42.79M | +264,162 | 0.00% |
| AIHC Capital Management Ltd | 3,828,460 | 3.69% | $41.46M | +1,368,909 | 39.77% |
| Alkeon Capital Management LLC | 3,739,096 | 3.61% | $40.49M | −765,000 | 0.05% |
| Column Group LLC | 3,540,777 | 3.42% | $38.35M | – | 43.53% |
| Siren, L.L.C. | 2,998,192 | 2.89% | $32.47M | – | 0.66% |
| FMR LLC | 2,635,475 | 2.54% | $28.54M | +201,395 | 0.00% |
| Citadel Advisors LLC | 2,595,299 | 2.50% | $28.11M | +172,558 | 0.00% |
| Goldman Sachs Group Inc | 2,451,796 | 2.37% | $26.55M | +976,084 | 0.00% |
| Geode Capital Management, LLC | 2,090,089 | 2.02% | $22.64M | +251,288 | 0.00% |
| First Turn Management, LLC | 2,017,284 | 1.95% | $21.85M | – | 2.34% |
| Orbimed Advisors LLC | 2,015,000 | 1.94% | $21.82M | −678,929 | 0.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 124M | 100.0% | 31 / 82 | 42 / 30 | 18M | 14M |
| Q1 2026 | 182 | 119M | 100.0% | 40 / 57 | 64 / 22 | 20M | 16M |
| Q4 2025 | 165 | 120M | 100.0% | 35 / 68 | 34 / 21 | 19M | 8M |
| Q3 2025 | 152 | 108M | 100.0% | 32 / 59 | 33 / 22 | 19M | 5M |
| Q2 2025 | 142 | 93M | 90.2% | 35 / 43 | 51 / 35 | 27M | 12M |
| Q1 2025 | 143 | 79M | 76.4% | 33 / 50 | 38 / 17 | 17M | 8M |
| Q4 2024 | 129 | 76M | 73.1% | 27 / 51 | 26 / 20 | 11M | 5M |
| Q3 2024 | 122 | 70M | 67.4% | 24 / 38 | 39 / 13 | 11M | 3M |
| Q2 2024 | 113 | 68M | 65.3% | 22 / 54 | 19 / 20 | 6M | 3M |
| Q1 2024 | 112 | 65M | 62.3% | 35 / 32 | 28 / 15 | 20M | 7M |
| Q4 2023 | 92 | 51M | 49.4% | 20 / 36 | 21 / 17 | 8M | 6M |
| Q3 2023 | 90 | 49M | 47.3% | 16 / 27 | 28 / 9 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ORIC | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,265,284 | 3.15% | $35.36M | 0.33% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,918,973 | 2.82% | $31.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,947,237 | 1.88% | $21.09M | 0.03% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,533,122 | 1.48% | $16.60M | 0.14% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,261,301 | 1.22% | $13.66M | 0.14% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,114,736 | 1.08% | $12.07M | 0.08% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 951,433 | 0.92% | $10.30M | 0.58% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 942,755 | 0.91% | $10.21M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 817,877 | 0.79% | $9.05M | 0.03% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 718,374 | 0.69% | $6.07M | 0.01% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 659,005 | 0.64% | $7.30M | 0.63% | Jul 31, 2026 |
| Vanguard Explorer Fund | 526,858 | 0.51% | $5.83M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 483,278 | 0.47% | $5.23M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 430,714 | 0.42% | $4.66M | 0.05% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 403,961 | 0.39% | $4.47M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jacob Chacko | PRESIDENT AND CEO, Director | 581,711 | 0.56% | Jan 6, 2026 |
| Dominic Piscitelli | Chief Financial Officer | 83,228 | 0.08% | Sep 29, 2026 |
| Pratik S. Multani | Chief Medical Officer | 68,149 | 0.07% | Jan 6, 2026 |
| Richard A. Heyman | Director | 244,972 | 0.24% | Jul 28, 2026 |
| Mardi Dier | Director | 0 | – | Jan 6, 2026 |
| Steven L. Hoerter | Director | – | – | Jan 6, 2026 |
| Lori Anne Kunkel | Director | 84,200 | 0.08% | Jan 6, 2026 |
| Angie You | Director | 28,000 | 0.03% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dominic Piscitelli Chief Financial Officer | Sep 28, 2026 | Option exercise | +13,400 | $4.36 | $58.42K | 83,228 |
| Dominic Piscitelli Chief Financial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −13,400 | $13.53 | $181.30K | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Sale(10b5-1 plan) | −500 | $13.51 | $6.76K | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Sale(10b5-1 plan) | −100 | $13.50 | $1.35K | 70,328 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Option exercise | +600 | $4.36 | $2.62K | 70,428 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Sale(10b5-1 plan) | −77,000 | $13.69 | $1.05M | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Option exercise | +25,000 | $6.00 | $150.00K | 146,828 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Option exercise | +52,000 | $4.36 | $226.72K | 121,828 |
| Richard A. Heyman Director | Jul 24, 2026 | Sale(10b5-1 plan) | −6,100 | $12.02 | $73.32K | 206,672 |
| Richard A. Heyman Director | Jul 24, 2026 | Sale(10b5-1 plan) | −7,000 | $12.02 | $84.14K | 38,300 |
| Richard A. Heyman Director | Jul 24, 2026 | Option exercise | +3,500 | $1.60 | $5.60K | 45,300 |
| Richard A. Heyman Director | Jul 6, 2026 | Sale(10b5-1 plan) | −300 | $12.00 | $3.60K | 212,772 |
| Dominic Piscitelli Chief Financial Officer | Feb 24, 2026 | Option exercise | +52,000 | $4.36 | $226.72K | 120,148 |
| Dominic Piscitelli Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −52,000 | $13.51 | $702.52K | 68,148 |
| Richard A. Heyman Director | Jan 16, 2026 | Sale(10b5-1 plan) | −3,500 | $12.00 | $42.00K | 41,800 |
| Richard A. Heyman Director | Jan 16, 2026 | Sale(10b5-1 plan) | −3,200 | $12.00 | $38.40K | 213,072 |
| Pratik S. Multani Chief Medical Officer | Dec 16, 2025 | Sale | −10,720 | $9.06 | $97.12K | 68,149 |
| Dominic Piscitelli Chief Financial Officer | Dec 16, 2025 | Sale | −10,720 | $9.06 | $97.12K | 68,148 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 16, 2025 | Sale | −33,374 | $9.06 | $302.37K | 581,711 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2025 | Option exercise | +29,333 | – | – | 78,869 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2025 | Option exercise | +29,333 | – | – | 78,868 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 15, 2025 | Option exercise | +83,666 | – | – | 615,085 |
| Lori Anne Kunkel Director | Dec 8, 2025 | Option exercise | +10,000 | $7.90 | $79.00K | 84,200 |
| Lori Anne Kunkel Director | Dec 4, 2025 | Option exercise | +5,534 | $3.75 | $20.75K | 74,200 |
| Jacob Chacko PRESIDENT AND CEO, Director | Oct 6, 2025 | Sale(10b5-1 plan) | −37,461 | $12.32 | $461.52K | 531,419 |
| Dominic Piscitelli Chief Financial Officer | Oct 6, 2025 | Option exercise | +11,000 | $4.36 | $47.96K | 59,317 |
| Dominic Piscitelli Chief Financial Officer | Oct 6, 2025 | Sale(10b5-1 plan) | −11,000 | $14.52 | $159.72K | 48,317 |
| Richard A. Heyman Director | Oct 3, 2025 | Option exercise | +1,447 | $3.75 | $5.43K | 45,300 |
| Richard A. Heyman Director | Oct 3, 2025 | Option exercise | +31,353 | $1.60 | $50.16K | 43,853 |
| Jacob Chacko PRESIDENT AND CEO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −53,001 | $12.05 | $638.66K | 568,880 |
| Jacob Chacko PRESIDENT AND CEO, Director | Sep 30, 2025 | Sale(10b5-1 plan) | −34,538 | $12.01 | $414.80K | 621,881 |
| Jacob Chacko PRESIDENT AND CEO, Director | Sep 22, 2025 | Sale(10b5-1 plan) | −125,000 | $10.80 | $1.35M | 656,419 |
| Dominic Piscitelli Chief Financial Officer | Jul 1, 2025 | Sale(10b5-1 plan) | −20,000 | $10.05 | $201.00K | 48,317 |
| Dominic Piscitelli Chief Financial Officer | Jun 24, 2025 | Sale(10b5-1 plan) | −32,466 | $10.50 | $340.89K | 68,317 |
| Dominic Piscitelli Chief Financial Officer | Jun 23, 2025 | Sale(10b5-1 plan) | −450 | $10.01 | $4.50K | 100,783 |
| Dominic Piscitelli Chief Financial Officer | Jun 23, 2025 | Sale(10b5-1 plan) | −584 | $10.00 | $5.84K | 101,233 |
| Angie You Director | Jun 23, 2025 | Buy | +1,403 | $9.43 | $13.23K | 28,000 |
| Angie You Director | Jun 20, 2025 | Buy | +26,597 | $9.39 | $249.75K | 26,597 |
| Dominic Piscitelli Chief Financial Officer | Jun 12, 2025 | Sale(10b5-1 plan) | −300 | $10.00 | $3.00K | 101,817 |
| Dominic Piscitelli Chief Financial Officer | Jun 11, 2025 | Sale(10b5-1 plan) | −1,276 | $10.00 | $12.76K | 103,817 |
| Dominic Piscitelli Chief Financial Officer | Jun 11, 2025 | Sale(10b5-1 plan) | −1,700 | $10.01 | $17.02K | 102,117 |
| Dominic Piscitelli Chief Financial Officer | Jun 10, 2025 | Sale(10b5-1 plan) | −324 | $10.00 | $3.24K | 105,093 |
| Dominic Piscitelli Chief Financial Officer | Jun 9, 2025 | Sale(10b5-1 plan) | −300 | $10.00 | $3.00K | 103,864 |
| Dominic Piscitelli Chief Financial Officer | Jun 6, 2025 | Sale(10b5-1 plan) | −2,600 | $10.01 | $26.03K | 104,164 |
| Lori Anne Kunkel Director | Mar 3, 2025 | Option exercise | +27,666 | $3.75 | $103.75K | 48,166 |
| Lori Anne Kunkel Director | Mar 3, 2025 | Option exercise | +20,500 | $6.33 | $129.77K | 68,666 |
| Pratik S. Multani Chief Medical Officer | Dec 16, 2024 | Sale | −8,850 | $8.28 | $73.28K | 46,765 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 16, 2024 | Sale | −24,660 | $8.28 | $204.18K | 778,648 |
| Dominic Piscitelli Chief Financial Officer | Dec 16, 2024 | Sale | −8,851 | $8.28 | $73.29K | 106,764 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2024 | Option exercise | +24,042 | – | – | 55,615 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 15, 2024 | Option exercise | +67,000 | – | – | 803,308 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2024 | Option exercise | +24,042 | – | – | 115,615 |
| Lori Anne Kunkel Director | Jun 3, 2024 | Option exercise | +20,500 | $3.75 | $76.88K | 20,500 |
| Jacob Chacko PRESIDENT AND CEO, Director | Mar 6, 2024 | Sale(10b5-1 plan) | −40,000 | $16.21 | $648.40K | 728,544 |
| Jacob Chacko PRESIDENT AND CEO, Director | Feb 7, 2024 | Sale(10b5-1 plan) | −26,042 | $12.30 | $320.32K | 768,544 |
| Jacob Chacko PRESIDENT AND CEO, Director | Feb 6, 2024 | Sale(10b5-1 plan) | −13,958 | $12.12 | $169.17K | 794,586 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2023 | Sale | −5,282 | $8.59 | $45.37K | 23,809 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2023 | Option exercise | +14,042 | – | – | 29,091 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2023 | Sale | −5,282 | $8.58 | $45.32K | 83,809 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2023 | Option exercise | −14,042 | – | – | 89,091 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard A, Heyman Director | Oct 1, 2026 | 7,600 | $102.37K | Oct 1, 2026 | Private Investment |
| Richard A, Heyman Director | Oct 1, 2026 | 8,100 | $109.11K | Oct 1, 2026 | Stock Option Exercise |
| Piscitelli Dominic Officer | Aug 26, 2026 | 229,500 | $3.10M | Aug 26, 2026 | Stock Option Exercise |
| Richard A, Heyman Director | Jul 6, 2026 | 6,400 | $76.80K | Jul 6, 2026 | Stock Option Exercise |
| Richard A, Heyman Director | Jul 6, 2026 | 7,000 | $84.00K | Jul 6, 2026 | Stock Option Exercise |
| Piscitelli Dominic Officer | Feb 24, 2026 | 52,000 | $702.00K | Feb 24, 2026 | Stock Option Exercise |
| Richard A, Heyman Director | Jan 16, 2026 | 6,400 | $76.80K | Jan 16, 2026 | Stock Option Exercise |
| Richard A, Heyman Director | Jan 16, 2026 | 7,000 | $84.00K | Jan 16, 2026 | Stock Option Exercise |
| Jacob Chacko Officer, Director | Dec 16, 2025 | 33,374 | $302.37K | Dec 16, 2025 | Restricted Stock Units |
| Pratik S. Multani Officer | Dec 16, 2025 | 10,720 | $97.13K | Dec 16, 2025 | Restricted Stock Units |
| Dominic Piscitelli Officer | Dec 16, 2025 | 10,720 | $97.13K | Dec 16, 2025 | Restricted Stock Units |
| Piscitelli Dominic Officer | Oct 6, 2025 | 50,000 | $725.00K | Oct 6, 2025 | Stock Option Exercise |
| Chacko Jacob Director, Officer | Sep 22, 2025 | 250,000 | $2.63M | Sep 22, 2025 | Open Market Purchase |
| Piscitelli Dominic Officer | Jun 6, 2025 | 60,000 | $540.00K | Jun 6, 2025 | Open Market Purchase |
| Dominic Piscitelli Officer | Dec 16, 2024 | 8,851 | $73.30K | Dec 16, 2024 | Restricted Stock Units |